medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 1

<< Back Next >>

Ann Hepatol 2011; 10 (1)

Treatment issues surrounding hepatitis C in renal transplantation: A review

Kim E, Ko HH, Yoshida EM

Language: English
References: 94
Page: 5-14
PDF size: 84.78 Kb.


ABSTRACT

Hepatitis C infection is prevalent in candidates for and recipients of solid organ transplants. In the renal transplant population, HCV infection has been shown to decrease long-term patient and graft survival. The outcomes of HCV in recipients of other solid organ transplants are yet to be established and prospective studies will be needed in the future. In the absence of effective and safe antiviral treatment for HCV infection in renal, heart, and lung transplant recipients, the management of these patients remains a challenge and has led to an increased focus on identifying and treating hepatitis C in patients prior to transplantation. Interferon-based therapy for HCV prior transplantation appears to improve outcomes after transplantation. On the other hand, post-transplant interferon therapy is associated with an increased risk of graft rejection. Given the paucity of information on HCV treatment in solid organ transplant recipients, there is a great need for large-scale, multi-centre randomized controlled trials to determine the optimal approach to HCV infection in this population. This article will summarize the current peer-reviewed literature focusing on the efficacy of amantadine, ribavirin and both standard and pegylated interferon in the treatment of chronic hepatitis C in renal, transplant recipients.


REFERENCES

  1. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-99.

  2. Pereira BJ. Hepatitis C infection and post-transplantation liver disease. Nephrol Dial Transplant 1995; 10(Suppl. 1): 58-67.

  3. Fishman JA, Rubin RH, Koziel MJ, Periera BJ. Hepatitis C virus and organ transplantation. Transplantation 1996; 62: 147-54.

  4. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.

  5. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 2007; 21(Suppl C): 5C-24C.

  6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

  7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  8. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38: 919-34.

  9. Morales JM, Campistol JM, Dominguez-Gil B. Hepatitis C virus infection and kidney transplantation. Semin Nephrol 2002; 22: 365-74.

  10. Hammoud H, Haem J, Laurent B, et al. Glomerular disease during HCV infection in renal transplantation. Nephrol Dial Transplant 1996; 11(Suppl 4): 54-5.

  11. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-70.

  12. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805.

  13. Huang CC, Liaw YF, Lai MK, Chu SH, Chuang CK, Huang JY. The clinical outcome of hepatitis C virus antibody-positive renal allograft recipients. Transplantation 1992; 53: 763-5.

  14. Roth D. Hepatitis C virus: the nephrologist’s view. Am J Kidney Dis 1995; 25: 3-16.

  15. Ponz E, Campistol JM, Barrera JM, et al. Hepatitis C virus antibodies in patients on hemodialysis and after kidney transplantation. Transplant Proc 1991; 23: 1371-2.

  16. Stempel CA, Lake J, Kuo G, Vincenti F. Hepatitis C—its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 1993; 55: 273-6.

  17. Berthoux F. Hepatitis C virus infection and disease in renal transplantation. Nephron 1995; 71: 386-94.

  18. Chan TM, Lok AS, Cheng IK. Hepatitis C in renal transplant recipients. Transplantation 1991; 52: 810-3.

  19. Klauser R, Franz M, Traindl O, et al. Hepatitis C antibody in renal transplant patients. Transplant Proc 1992; 24: 286-8.

  20. Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129-33.

  21. Roth D, Zucker K, Cirocco R, et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61: 886-9.

  22. Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454-60.

  23. Alric L, Di-Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494-9.

  24. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704-12.

  25. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11: 1343-53.

  26. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004; 19(Suppl. 3): iii72-6.

  27. Younossi ZM, Braun WE, Protiva DA, Gifford RW, Jr., Straffon RA. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999; 67: 272-5.

  28. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5: 2433-40.

  29. Cosio FG, Sedmak DD, Henry ML, et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1054-9.

  30. Morales JM, Campistol JM, Andres A, Rodicio JL. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997; 6: 511-5.

  31. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29: 608-14.

  32. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53: 1374-81.

  33. Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007; 83: 853-7.

  34. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferonalpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999; 31: 2887-9.

  35. Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001; 55: 220-6.

  36. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil- Vernet S, Grinyo JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003;3:357-60.

  37. Fabrizi F, Martin P, Bunnapradist S. Treatment of chronic viral hepatitis in patients with renal disease. Gastroenterol Clin North Am 2004; 33: 655-70, xi.

  38. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.

  39. Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507-9.

  40. Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha- 2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412-8.

  41. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176: 1614-7.

  42. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-23.

  43. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704-9.

  44. Casanovas. Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. Transplant Proc 1995; 27: 2229.

  45. Casanovas-Taltavull T, Baliellas C, Benasco C, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96: 1170-7.

  46. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. J Viral Hepat 2001; 8: 287-92.

  47. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis Cassociated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573-80.

  48. Sporea I, Sirli R, Golea O, Totolici C, Danila M, Popescu A. Peg- Interferon Alfa 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results. Rom J Gastroenterol 2004; 13: 99-102.

  49. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-21.

  50. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 575-80.

  51. Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha- interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 2104-6.

  52. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512-6.

  53. Kakimoto K, Takahara S, Kokado Y, et al. [A case of allograft rejection induced by the interferon-alpha therapy to hepatitis type C after renal transplantation]. Hinyokika Kiyo 1994; 40: 529-32.

  54. Baid S, Tolkoff-Rubin N, Saidman S, et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74-8.

  55. Fabrizi F, Martin P, et al. Management of hepatitis B and C virus infection before and after renal transplantation. Curr Opin Organ Transplant 2006; 11: 583.

  56. Therret E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994; 58: 625-8.

  57. Magnone M, Holley JL, Shapiro R, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068-70.

  58. Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20: 677-83.

  59. Shu KH, Lan JL, Wu MJ, et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004; 77: 1894-6.

  60. Tang S, Cheng IK, Leung VK, et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875-8.

  61. Zeman M, Campbell P, Bain VG. Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol 2006; 20: 427-31.

  62. Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colledan M, Strazzabosco M. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007; 41: 216-20.

  63. Mukherjee S, Ariyarantha K. Successful Hepatitis C Eradication With Preservation of Renal Function in a Liver/kidney Transplant Recipient Using Pegylated Interferon and Ribavirin. Transplantation 2007; 84: 1374-5.

  64. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42: 1681-7.

  65. Tabone M, Ercole E, Zaffino C, Sallio Bruno F, Pera A, Bonino F. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol 1998; 30: 611-3.

  66. Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol 1999; 31: 130-4.

  67. Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. Nephrol Dial Transplant 2000; 15(Suppl 8): 74-6.

  68. Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol 2004; 30: 110-4.

  69. Calanca LN, Fehr T, Jochum W, et al. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. J Clin Virol 2007; 39: 54-8.

  70. Adinolfi LE, Andreana A, Utili R, Zampino R, Ragone E, Ruggiero G. HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Am J Gastroenterol 1998; 93: 2162-6.

  71. Gane EJ, Tibbs CJ, Ramage JK, Portmann BC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995; 8: 61-4.

  72. Pham HP, Feray C, Samuel D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998; 54: 1311-9.

  73. Cattral MS, Hemming AW, Wanless IR, et al. Outcome of longterm ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 1999; 67: 1277-80.

  74. Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997; 29: 783.

  75. Kamar N, Sandres-Saune K, Selves J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-92.

  76. Fontaine H, Vallet-Pichard A, Equi-Andrade C, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853-7.

  77. Karaca C, Besisik F, Akyuz F, Dincer D, Sever MS, Okten A. Ribavirin treatment in patients with chronic hepatitis C infection who had renal transplantation. Dig Surg 2005; 22: 113.

  78. Fontaine. Histopathological efficacy of ribavirin monotherapy in hepatitis C virus positive renal transplant patients. Transplantation 2005; 79: 1771.

  79. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000; 69: 991-4.

  80. Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989-90.

  81. Kovarik J, Mayer G, Pohanka E, et al. Adverse effect of lowdose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988; 45:402-5.

  82. Black M, Peters M. Alpha-interferon treatment of chronic hepatitis C: need for accurate diagnosis in selecting patients. Ann Intern Med 1992; 116: 86-8.

  83. Durlik M, Gaciong Z, Rowinska D, et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11(Suppl. 1): S135-9.

  84. Toth CM, Pascual M, Chung RT, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66: 1254-8.

  85. Luciani G, Bossola M, Muscaritoli M, et al. Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C. J Nephrol 2003; 16: 417-20.

  86. Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin Gastroenterol Hepatol 2005; 3: S113-7.

  87. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843-61.

  88. Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000;70:255-61.

  89. Chan TM, Wu PC, Lok AS, Lai CL, Cheng IK. Clinicopathological features of hepatitis C virus antibody negative fatal chronic hepatitis C after renal transplantation. Nephron 1995; 71: 213-7.

  90. Heydtmann M, Freshwater D, Dudley T, et al. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 2006; 6: 825-33.

  91. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160: 3487-93.

  92. Konishi I, Horiike N, Michitaka K, et al. Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy. Intern Med 2004; 43: 931-4.

  93. Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis 2004; 24(Suppl. 2): 33-8.

  94. Carbognin SJ, Solomon NM, Yeo FE, et al. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am J Transplant 2006; 6: 1746-51.




2020     |     www.medigraphic.com